|1.||Iversen, Patrick L: 7 articles (01/2015 - 01/2003)|
|2.||Sazani, Peter: 4 articles (11/2013 - 02/2010)|
|3.||Devi, Gayathri R: 4 articles (06/2008 - 01/2003)|
|4.||Weller, Doreen L: 3 articles (05/2011 - 05/2005)|
|5.||Wilton, Steve D: 2 articles (01/2014 - 08/2011)|
|6.||Takeda, Shin'ichi: 2 articles (12/2013 - 01/2010)|
|7.||Aoki, Yoshitsugu: 2 articles (12/2013 - 01/2010)|
|8.||Wood, Matthew J A: 2 articles (12/2013 - 08/2011)|
|9.||Nakamura, Akinori: 2 articles (12/2013 - 01/2010)|
|10.||Yokota, Toshifumi: 2 articles (12/2013 - 01/2010)|
06/01/2008 - "Subcutaneous administration of AVI-4126 at local tumor site (50 microg/day) for 3 cycles of 5 days a week starting day 1 post-tumor cell implantation showed significantly decreased tumor burden, number of tumorlets formed in the lung in comparison to saline or control PMO treatment groups, although no significant reduction of the subcutaneous tumor was observed. "
06/01/2008 - "The study results are significant in the development of novel anti-tumoral therapeutic strategies directed to c-MYC-overexpressing tumors and establish AVI-4126 as a strong clinical candidate for metastatic disease."
05/15/2005 - "The study objectives were to evaluate safety, to determine AVI-4126 concentration in tissue samples of the tumors, and to examine the distribution of AVI-4126 (margin versus tumor core). "
05/15/2005 - "AVI-4126, a PMO targeted against c-MYC, has been extensively characterized in multiple cancer and other disease models and is currently in human clinical trials. "
01/01/2003 - "Immunoblot and HPLC-based analysis of tumor lysates at the end of the study confirmed c-Myc inhibition and detection of intact AVI-4126, respectively. "
06/01/2010 - "In this study we investigated whether persistently infected HeLa cells could be cured of EAV infection by treatment with an antisense peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) designed to target the 5'-terminal region of the EAV genome. "
01/01/2015 - "A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infection."
|3.||Prostatic Neoplasms (Prostate Cancer)
07/01/2003 - "The present study demonstrates that inhibition of c-Myc expression by antisense phosphorodiamidate morpholino oligomer is a promising new and safe therapeutic strategy for prostate cancer."
07/01/2003 - "The data reveal that AVI-4126 targets and inhibits c-myc translation in a sequence-specific manner and causes significant growth inhibition and apoptosis in prostate cancer cells and in s.c. "
07/01/2003 - "The purpose of this study was to evaluate the bioavailability and efficacy of a novel antisense phosphorodiamidate morpholino oligomer directed against c-myc, AVI-4126, in PC-3 androgen-independent human prostate cancer xenograft murine model and its safety in a Phase I human clinical study. "
|4.||Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker)
12/15/2013 - "Phosphorodiamidate morpholino oligomer (PMO)-mediated exon skipping is among the more promising approaches to the treatment of several neuromuscular disorders including Duchenne muscular dystrophy. "
11/01/2013 - "In prior open-label studies, eteplirsen, a phosphorodiamidate morpholino oligomer, enabled dystrophin production in Duchenne muscular dystrophy (DMD) with genetic mutations amenable to skipping exon 51. "
08/13/2011 - "We report clinical safety and biochemical efficacy from a dose-ranging study of intravenously administered AVI-4658 phosphorodiamidate morpholino oligomer (PMO) in patients with Duchenne muscular dystrophy. "
08/13/2011 - "Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study."
01/01/2014 - "In contrast, multiexon skipping of exons 2-7 to generate a Becker muscular dystrophy-like dystrophin transcript was more challenging and could only be induced efficiently with the phosphorodiamidate morpholino oligomer chemistry. "
|5.||Porcine Reproductive and Respiratory Syndrome (PRRS)
|1.||phosphorodiamidate morpholino oligomer
|6.||Messenger RNA (mRNA)
|7.||Small Interfering RNA (siRNA)
|10.||DNA (Deoxyribonucleic Acid)
|1.||Heterologous Transplantation (Xenotransplantation)